Hessian Labs is redefining cancer diagnostics by moving beyond the limits of tissue biopsies, imaging, and DNA mutation–driven models.

Our approach harnesses platelet proteomics—a non-invasive blood test that reveals real-time disease biology across the body. Platelets selectively sequester proteins from the tumor microenvironment, creating a dynamic and enriched signal of cancer progression, therapeutic response, and biological behavior.

Rather than measuring what cancer could become, we measure what it is doing now.

At the center of this innovation is ClariaIQ™, our proprietary molecular informatics platform. ClariaIQ decodes the complex proteomic signatures carried by platelets and translates them into clinically actionable insights that support earlier detection, more precise risk stratification, treatment monitoring, and better clinical decision support.

This creates a level of biological resolution and clinical precision that traditional genomic and tissue-based approaches cannot provide.